TCGA-OR-A5LP-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.417
- IL6_JAK_STAT3_SIGNALING+0.408
- INTERFERON_GAMMA_RESPONSE+0.403
- INTERFERON_ALPHA_RESPONSE+0.402
- ALLOGRAFT_REJECTION+0.381
- ANGIOGENESIS+0.343
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.329
- TNFA_SIGNALING_VIA_NFKB+0.312
- IL2_STAT5_SIGNALING+0.303
- COMPLEMENT+0.295
Top 10 suppressed
- E2F_TARGETS-0.455
- G2M_CHECKPOINT-0.435
- MYC_TARGETS_V1-0.365
- DNA_REPAIR-0.336
- PANCREAS_BETA_CELLS-0.251
- CHOLESTEROL_HOMEOSTASIS-0.242
- MYC_TARGETS_V2-0.225
- SPERMATOGENESIS-0.174
- FATTY_ACID_METABOLISM-0.113
- PEROXISOME-0.099
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JWSR581E | low-grade glioma | — | 0.904 |
| 2 | TCGA-CV-7104-01A-11R-2016-07 | — | — | 0.887 |
| 3 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.884 |
| 4 | BS_1RXZ3BP7 | low-grade glioma | — | 0.884 |
| 5 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.883 |
| 6 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.882 |
| 7 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.882 |
| 8 | BS_F8N6CFQE | low-grade glioma | — | 0.882 |
| 9 | SRR22247245 | — | cohortMD2 | 0.881 |
| 10 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.417 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.408 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.403 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.402 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.381 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.343 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.329 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.312 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.303 | Idelalisib | — uncovered |
| COMPLEMENT | 0.295 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.289 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.287 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.242 | Inavolisib | — uncovered |
| COAGULATION | 0.236 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.225 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.223 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.203 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.191 | Inavolisib | — uncovered |
| APOPTOSIS | 0.183 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.177 | Inavolisib | — uncovered |